Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · see citing works

TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data

Colaprico, A., Silva, T. C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabedot, T. S., Malta, T. M., Pagnotta, S. M., Castiglioni, I., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1507 · Cited by 4,137 · see citing works

Targeting multidrug resistance in cancer

Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · see citing works

Clonal heterogeneity and tumor evolution: past, present, and the future

McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · see citing works

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,698 · see citing works

Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries

Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,562 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,198 · see citing works

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V. G., Liszkay, G., Maio, M., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,061 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,916 · see citing works

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · see citing works

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · see citing works

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,211 · see citing works

Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody

Burton, D. R., Pyati, J., Koduri, R. K., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N. M., Nara, P. L., et al. (1994) · Science · doi:10.1126/science.7973652 · Cited by 1,100 · see citing works

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · see citing works

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · see citing works

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 828 · see citing works

<i>In vivo</i> Switching of Human Melanoma Cells between Proliferative and Invasive States

Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743 · see citing works

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639 · see citing works

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 623 · see citing works

Antibody–drug conjugates for cancer therapy

Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606 · see citing works

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature

Hoek, K. S., Schlegel, N. C., Brafford, P. A., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 554 · see citing works

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O. O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 526 · see citing works

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez‐Canales, J., Wistuba, I. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 526 · see citing works

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507 · see citing works

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 502 · see citing works

A combinatorial strategy for treating KRAS-mutant lung cancer

Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403 · see citing works

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N. M., Wood, C. G., Matin, S. F., et al. (2015) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 400 · see citing works

The Implications of Clonal Genome Evolution for Cancer Medicine

Aparicio, S. A. J. R., & Caldas, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204892 · Cited by 350 · see citing works

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325 · see citing works

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

Long, G. V., Grob, J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Lane, S. R., Mak, C., Legenne, P., Flaherty, K. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30578-2 · Cited by 316 · see citing works

High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice

Fishwild, D. M., O'Donnell, S. L., Bengoechea, T. G., Hudson, D., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266 · see citing works

New developments for antibody-drug conjugate-based therapeutic approaches

de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 254 · see citing works

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

Hong, C., Lay, J., Huang, J.-S., Cheng, A., Tang, J., Lin, M., Lai, G., & Chuang, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.017 · Cited by 234 · see citing works

An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

Breij, E. C. W., de Goeij, B. E. C. G., Verploegen, S., Schuurhuis, D. H., Amirkhosravi, A., Francis, J., Miller, V. B., Houtkamp, M., Bleeker, W. K., Satijn, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2440 · Cited by 227 · see citing works

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα

Smith, M. P., Sánchez‐Laorden, B. L., O’Brien, K., Brunton, H., Ferguson, J., Young, H. L., Dhomen, N. S., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1007 · Cited by 225 · see citing works

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

Chen, R., Hou, J., Newman, E. M., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 217 · see citing works

Reprogramming the immunological microenvironment through radiation and targeting Axl

Aguilera, T. A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M. S., Hui, A. B., Stehr, H., von Eyben, R., Jiang, D., Ellies, L. G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13898 · Cited by 192 · see citing works

Analysis of the genome to personalize therapy for melanoma

Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 167 · see citing works

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6

Loges, S., Schmidt, T., Tjwa, M., Geyte, K. V., Lievens, D., Lutgens, E., Vanhoutte, D., Borgel, D., Plaisance, S., Hoylaerts, M., et al. (2009) · Blood · doi:10.1182/blood-2009-06-228684 · Cited by 163 · see citing works

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 163 · see citing works

Axl activates autocrine transforming growth factor‐β signaling in hepatocellular carcinoma

Reichl, P., Dengler, M., van Zijl, F., Huber, H., Führlinger, G., Reichel, C., Sieghart, W., Peck‐Radosavljevic, M., Grubinger, M., & Mikulits, W. (2014) · Hepatology · doi:10.1002/hep.27492 · Cited by 157 · see citing works

Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling

Wang, C., Jin, H., Wang, N., Fan, S., Wang, Y., Zhang, Y., Lin, W., Tao, X., Gu, D., Zhao, F., et al. (2016) · Theranostics · doi:10.7150/thno.15083 · Cited by 149 · see citing works

Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts

Kemper, K., Krijgsman, O., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Song, J., Kuilman, T., Vis, D. J., Wessels, L. F. A., Voest, E. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404914 · Cited by 140 · see citing works

A simple, robust and highly efficient transient expression system for producing antibodies

Vink, T., Oudshoorn-Dickmann, M., Roza, M., Reitsma, J.-J., & de Jong, R. N. (2013) · Methods · doi:10.1016/j.ymeth.2013.07.018 · Cited by 135 · see citing works

ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT

Debruyne, D. N., Bhatnagar, N., Sharma, B., Luther, W., Moore, N. F., Cheung, N., Gray, N. S., & George, R. E. (2015) · Oncogene · doi:10.1038/onc.2015.434 · Cited by 119 · see citing works

BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

Kemper, K., Krijgsman, O., Kong, X., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Velden, D. L. V. D., Bleijerveld, O. B., Kuilman, T., Kluin, R. J. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.064 · Cited by 82 · see citing works

The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma

Cichoń, M. A., Szentpétery, Z., Caley, M. P., Papadakis, E. S., Mackenzie, I. C., Brennan, C. H., & O’Toole, E. A. (2013) · Oncogene · doi:10.1038/onc.2013.388 · Cited by 75 · see citing works

Cisplatin influences acquisition of resistance to molecular‐targeted agents through epithelial–mesenchymal transition‐like changes

Kurokawa, M., Ise, N., Omi, K., Goishi, K., & Higashiyama, S. (2013) · Cancer Science · doi:10.1111/cas.12171 · Cited by 52 · see citing works

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib

Xu, W., Wei, Y., Wu, S., Wang, Y., Wang, Z., Sun, Y., Cheng, S. Y., & Wu, J. (2015) · Cell & Bioscience · doi:10.1186/2045-3701-5-7 · Cited by 52 · see citing works

No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients

Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 47 · see citing works

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells

Bansal, N., Mishra, P. J., Stein, M. N., DiPaola, R. S., & Bertino, J. R. (2015) · Oncotarget · doi:10.18632/oncotarget.4148 · Cited by 40 · see citing works

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy

Creedon, H., Gómez-Cuadrado, L., Tarnauskaitė, Ž., Balla, J., Canel, M., MacLeod, K. G., Serrels, B., Fraser, C., Unciti‐Broceta, A., Tracey, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7317 · Cited by 33 · see citing works

MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma

Asundi, J., Lacap, J. A., Clark, S., Nannini, M., Roth, L. A., & Polakis, P. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0446 · Cited by 24 · see citing works

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer

Creedon, H., Byron, A., Main, J., Hayward, L., Klinowska, T. C. M., & Brunton, V. G. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140109 · Cited by 19 · see citing works

Translation rewiring at the heart of phenotype switching in melanoma

Leucci, E., Close, P., & Marine, J. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12583 · Cited by 5 · see citing works

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,175 · see citing works

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771 · see citing works

Antibody–Drug Conjugates: A Comprehensive Review

Khongorzul, P., Ling, C., Khan, F. U., Ihsan, A. U., & Zhang, J. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 796 · see citing works

The great escape: tumour cell plasticity in resistance to targeted therapy

Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 756 · see citing works

Non-genetic mechanisms of therapeutic resistance in cancer

Marine, J., Dawson, S., & Dawson, M. (2020) · Nature Reviews. Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 617 · see citing works

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 498 · see citing works

Phenotype plasticity as enabler of melanoma progression and therapy resistance

Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381 · see citing works

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 361 · see citing works

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunitiesPreprint

Rambow, F., Marine, J., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 316 · see citing works

Drug resistance in cancer: mechanisms and tackling strategies

Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 312 · see citing works

Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities

Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 301 · see citing works

Many ways to resistance: How melanoma cells evade targeted therapies

Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 273 · see citing works

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.014 · Cited by 259 · see citing works

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer

Tulchinsky, E. M., Demidov, O. N., Kriajevska, M. V., Barlev, N. A., & Имянитов, Е. Н. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.003 · Cited by 209 · see citing works

Rational Cancer Treatment Combinations: An Urgent Clinical Need

Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 216 · see citing works

Melanoma models for the next generation of therapies

Patton, E. E., Mueller, K. L., Adams, D. J., Anandasabapathy, N., Aplin, A. E., Bertolotto, C., Bosenberg, M., Ceol, C. J., Burd, C. E., Chi, P., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.011 · Cited by 204 · see citing works

Antibody–drug conjugates: in search of partners of choice

Fuentes‐Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.01.003 · Cited by 202 · see citing works

The journey from melanocytes to melanoma

Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 202 · see citing works

Precision medicine for human cancers with Notch signaling dysregulation (Review)

Katoh, M., & Katoh, M. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4418 · Cited by 196 · see citing works

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · see citing works

Current Advances in the Treatment of BRAF-Mutant Melanoma

Patel, H. M., Yacoub, N., Mishra, R., White, A., Yuan, L., Alanazi, S., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12020482 · Cited by 176 · see citing works

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

Wei, Q., Li, P., Yang, T. K., Zhu, J., Sun, L., Zhang, Z., Wang, L., Tian, X., Chen, J., Hu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01509-2 · Cited by 169 · see citing works

Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness

Hass, R., von der Ohe, J., & Ungefroren, H. (2020) · Cancers · doi:10.3390/cancers12123716 · Cited by 154 · see citing works

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

Ahmed, F., & Haass, N. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00173 · Cited by 148 · see citing works

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129 · see citing works

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

Boshuizen, J., Vredevoogd, D. W., Krijgsman, O., Ligtenberg, M. A., Blankenstein, S. A., de Bruijn, B., Frederick, D. T., Kenski, J. C. N., Parren, M., Brüggemann, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17739-8 · Cited by 125 · see citing works

SAMMSON fosters cancer cell fitness by concertedly enhancing mitochondrial and cytosolic translation

Vendramin, R., Verheyden, Y., Ishikawa, H., Goedert, L., Nicolas, É., Saraf, K., Armaos, A., Ponti, R. D., Izumikawa, K., Mestdagh, P., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0143-4 · Cited by 124 · see citing works

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer

Okura, N., Nishioka, N., Yamada, T., Taniguchi, H., Tanimura, K., Katayama, Y., Yoshimura, A., Watanabe, S., Kikuchi, T., Shiotsu, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2321 · Cited by 120 · see citing works

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Passaro, A., Janne, P. A., & Peters, S. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00013 · Cited by 119 · see citing works

Biology of Melanoma

Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 111 · see citing works

ZEB1 transcription factor promotes immune escape in melanoma

Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Bouar, M. L., Balme, B., Tondeur, G., de la Fouchardière, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003484 · Cited by 96 · see citing works

TAM family kinases as therapeutic targets at the interface of cancer and immunity

DeRyckere, D., Huelse, J. M., Earp, H. S., & Graham, D. K. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00813-7 · Cited by 98 · see citing works

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

Kim, D., Bach, D., Fan, Y., Luu, T.-T.-T., Hong, J., Park, H. J., & Lee, S. K. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1601-6 · Cited by 96 · see citing works

EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment

Tang, Y., Durand, S., Dalle, S., & Caramel, J. (2020) · Cancers · doi:10.3390/cancers12082154 · Cited by 96 · see citing works

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer

Tanaka, M., & Siemann, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189953 · Cited by 94 · see citing works

Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling

Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K., & Spencer, S. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21549-x · Cited by 94 · see citing works

ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL

Pietrobono, S., Anichini, G., Sala, C., Manetti, F., Almada, L. L., Pepe, S., Carr, R. M., Paradise, B. D., Sarkaria, J. N., Davila, J. I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19575-2 · Cited by 90 · see citing works

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition

Engelsen, A. S. T., Lotsberg, M. L., Khouzam, R. A., Thiery, J. P., Lorens, J. B., Chouaı̈b, S., & Terry, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869676 · Cited by 92 · see citing works

Immunological effects of BRAF+MEK inhibition

Ascierto, P. A., & Dummer, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468955 · Cited by 88 · see citing works

Cell plasticity in cancer cell populations

Shen, S., & Clairambault, J. (2020) · F1000Research · doi:10.12688/f1000research.24803.1 · Cited by 87 · see citing works

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review

Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 86 · see citing works

Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

Gauzy, L., Sassoon, I., & Brun, M. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220912955 · Cited by 87 · see citing works

AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity

Terry, S., Abdou, A., Engelsen, A. S. T., Buart, S., Dessen, P., Corgnac, S., Collares, D., Meurice, G., Gausdal, G., Baud, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0903 · Cited by 80 · see citing works

Targeting to Tumor-Harbored Bacteria for Precision Tumor Therapy

Song, W., Zheng, D., Zeng, S.-M., Zeng, X., & Zhang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c08555 · Cited by 79 · see citing works

Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review

Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 78 · see citing works

Therapeutic targeting of the functionally elusive TAM receptor family

Miao, Y. R., Rankin, E. B., & Giaccia, A. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00846-8 · Cited by 84 · see citing works

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Zhang, L., Liang, Y., Li, S., Zeng, F., Meng, Y., Chen, Z., Liu, S., Tao, Y., & Yu, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0989-z · Cited by 73 · see citing works

AXL as a Target in Breast Cancer Therapy

Colavito, S. A. (2020) · Journal of Oncology · doi:10.1155/2020/5291952 · Cited by 70 · see citing works

Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment

Diener, J., & Sommer, L. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0351 · Cited by 64 · see citing works

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Boshuizen, J., Pencheva, N., Krijgsman, O., Altimari, D. M. D., Castro, P. G., de Bruijn, B., Ligtenberg, M. A., den Heuvel, E. G.-V., Vredevoogd, D. W., Song, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0434 · Cited by 71 · see citing works

The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview

Wium, M., Paccez, J. D., & Zerbini, L. F. (2018) · Cells · doi:10.3390/cells7100166 · Cited by 68 · see citing works

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy

Aggarwal, D., Yang, J., Salam, M. A., Sengupta, S., Al-Amin, M. Y., Mustafa, S., Khan, M. A., Huang, X., & Pawar, J. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203073 · Cited by 71 · see citing works

Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy

Badarni, M., Prasad, M., Balaban, N., Zorea, J., Yegodayev, K. M., Joshua, B., Dinur, A. B., Grenman, R. A., Rotblat, B., Cohen, L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125341 · Cited by 69 · see citing works

Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy

Huang, F., Santinon, F., González, R. E. F., & Rincon, S. V. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756001 · Cited by 61 · see citing works

Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

Redondo-Muñoz, M., Rodríguez‐Baena, F. J., Aldaz, P., Caballé, A., Moncho-Amor, V., Otaegi-Ugartemendia, M., Carrasco‐García, E., Olías-Arjona, A., Lasheras-Otero, I., Santamaría, E., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00861-4 · Cited by 61 · see citing works

Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma

Vendramin, R., Katopodi, V., Cinque, S., Konnova, A., Knezevic, Z., Adnane, S., Verheyden, Y., Karras, P., Demesmaeker, E., Bosisio, F. M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210571 · Cited by 54 · see citing works

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58 · see citing works

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer

Koopman, L. A., Terp, M. G., Zom, G. G., Janmaat, M. L., Jacobsen, K., den Heuvel, E. G.-V., Brandhorst, M., Forssmann, U., Bree, F. D., Pencheva, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128199 · Cited by 58 · see citing works

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients

Hilke, F. J., Sinnberg, T. W., Gschwind, A., Niessner, H., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Bonzheim, I., Röcken, M., Rieß, O., et al. (2020) · Cancers · doi:10.3390/cancers12092359 · Cited by 56 · see citing works

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Adam‐Artigues, A., Arenas, E. J., Martínez, A., Brasó‐Maristany, F., Cervera, R., Tormo, E., Hernándo, C., Martínez, M. T., Carbonell‐Asins, J. A., Simón, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk2746 · Cited by 57 · see citing works

Heterogeneity in Melanoma

Ng, M. F., Simmons, J. L., & Boyle, G. M. (2022) · Cancers · doi:10.3390/cancers14123030 · Cited by 56 · see citing works

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

Hartman, M. L., Sztiller-Sikorska, M., Gajos-Michniewicz, A., & Czyż, M. (2020) · Cells · doi:10.3390/cells9010142 · Cited by 56 · see citing works

SMAD signaling promotes melanoma metastasis independently of phenotype switching

Tuncer, E., Calçada, R. R., Zingg, D., Varum, S., Cheng, P. F., Freiberger, S. N., Deng, C., Kleiter, I., Levesque, M. P., Dummer, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci94295 · Cited by 55 · see citing works

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

Sang, Y. B., Kim, J.-H., Kim, C.-G., Hong, M. H., Kim, H. R., Cho, B. C., & Lim, S. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811247 · Cited by 56 · see citing works

AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew

Auyez, A., Sayan, E., Kriajevska, M. V., & Tulchinsky, E. M. (2021) · Cancers · doi:10.3390/cancers13194864 · Cited by 50 · see citing works

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Ramkumar, K., Stewart, C. A., Cargill, K. R., Corte, C. M. D., Wang, Q., Shen, L., Diao, L., Cardnell, R. J., Peng, D. H., Rodriguez, B. L., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0414 · Cited by 53 · see citing works

Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors

Westerhout, E. M., Hamdi, M., Stroeken, P. J. M., Nowakowska, N. E., Lakeman, A., van Arkel, J., Hasselt, N. E., Bleijlevens, B., Akogul, N., Haneveld, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1621 · Cited by 49 · see citing works

Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 47 · see citing works

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

Zammarchi, F., Havenith, K. E., Chivers, S., Hogg, P., Bertelli, F., Tyrer, P., Janghra, N., Reinert, H. W., Hartley, J. A., & van Berkel, P. H. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0715 · Cited by 48 · see citing works

Therapeutic aspects of the Axl/Gas6 molecular system

Stasi, R. D., Rosa, L. D., & D’Andrea, L. D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.022 · Cited by 45 · see citing works

Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., & Wei, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00493-8 · Cited by 42 · see citing works

New Technologies Bloom Together for Bettering Cancer Drug Conjugates

Jin, Y., Zakeri, S. E., Bahal, R., & Wiemer, A. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000499 · Cited by 41 · see citing works

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy

Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 40 · see citing works

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

Lucas, A. T., Moody, A., Schorzman, A. N., & Zamboni, W. C. (2021) · Antibodies · doi:10.3390/antib10030030 · Cited by 40 · see citing works

Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment

Kharouf, N., Flanagan, T. W., Hassan, S.-Y., Shalaby, H., Khabaz, M., Hassan, S.-L., Megahed, M., Haïkel, Y., Santourlidis, S., & Hassan, M. (2023) · Cancers · doi:10.3390/cancers15123147 · Cited by 40 · see citing works

Phosphatidylserine receptor-targeting therapies for the treatment of cancer

Park, M., & Kang, K. W. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01167-4 · Cited by 39 · see citing works

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma

Hoffmann, R. M., Crescioli, S., Mele, S., Sachouli, E., Cheung, A., Chui, C. K., Andriollo, P., Jackson, P. J., Lacy, K. E., Spicer, J. F., et al. (2020) · Cancers · doi:10.3390/cancers12041029 · Cited by 39 · see citing works

Snail promotes the generation of vascular endothelium by breast cancer cells

Chang, Z., Zhang, Y., Liu, J., Zheng, Y., Li, H., Kong, Y., Li, P., Peng, H., Shi, Y., Cao, B., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2651-5 · Cited by 38 · see citing works

Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Jin, R., Liu, L., Xing, Y., Meng, T., Ma, L., Pei, J., Cong, Y., Zhang, X., Ren, Z., Wang, X., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0076 · Cited by 35 · see citing works

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35 · see citing works

Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential

Ceci, C., Lacal, P. M., & Graziani, G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108106 · Cited by 35 · see citing works

Antibody-drug Conjugate Targets, Drugs, and Linkers

Teicher, B. A., & Morris, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220224110538 · Cited by 35 · see citing works

AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer

Du, W., Phinney, N. Z., Huang, H., Wang, Z., Westcott, J. M., Toombs, J. E., Zhang, Y., Beg, M. S., Wilkie, T. M., Lorens, J. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0860 · Cited by 34 · see citing works

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma

Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A. H., Journé, F., & Ghanem, G. (2022) · Cells · doi:10.3390/cells11071157 · Cited by 34 · see citing works

The future of targeted kinase inhibitors in melanoma

Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 33 · see citing works

Does Axl have potential as a therapeutic target in pancreatic cancer?

Du, W., & Brekken, R. A. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1527315 · Cited by 31 · see citing works

Systems-level network modeling deciphers the master regulators of phenotypic plasticity and heterogeneity in melanoma

Pillai, M., & Jolly, M. K. (2021) · iScience · doi:10.1016/j.isci.2021.103111 · Cited by 32 · see citing works

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

Czyż, M., Sztiller-Sikorska, M., Gajos-Michniewicz, A., Osrodek, M., & Hartman, M. L. (2019) · Journal of Oncology · doi:10.1155/2019/1697913 · Cited by 31 · see citing works

Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation

Melixetian, M. B., Bossi, D., Mihailovich, M., Punzi, S., Barozzi, I., Marocchi, F., Cuomo, A., Bonaldi, T., Testa, G., Marine, J., et al. (2021) · EMBO Reports · doi:10.15252/embr.202050852 · Cited by 31 · see citing works

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations

Patwardhan, G. A., Marczyk, M., Wali, V. B., Stern, D. F., Pusztai, L., & Hatzis, C. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00270-4 · Cited by 31 · see citing works

Hierarchy of TGFβ/SMAD, Hippo/YAP/TAZ, and Wnt/β-catenin signaling in melanoma phenotype switching

Lüönd, F., Pirkl, M., Hisano, M., Prestigiacomo, V., Kalathur, R. K. R., Beerenwinkel, N., & Christofori, G. (2021) · Life Science Alliance · doi:10.26508/lsa.202101010 · Cited by 29 · see citing works

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 30 · see citing works

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

Liu, X., Deng, J., Zhang, R., Xing, J., Wu, Y., Chen, W., Liang, B., Xing, D., Xu, J., & Zhang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1335252 · Cited by 28 · see citing works

New Insights into the Phenotype Switching of Melanoma

Pagliuca, C., Leo, L. D., & Zio, D. D. (2022) · Cancers · doi:10.3390/cancers14246118 · Cited by 28 · see citing works

CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance

Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 28 · see citing works

Nongenetic Mechanisms of Drug Resistance in Melanoma

Rebecca, V. W., & Herlyn, M. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033533 · Cited by 27 · see citing works

Antibody-Drug Conjugates: Patient and Treatment Selection

Makawita, S., & Meric‐Bernstam, F. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280775 · Cited by 26 · see citing works

ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies

Amani, N., Dorkoosh, F. A., & Mobedi, H. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191121145109 · Cited by 27 · see citing works

AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage

Pei, J., Wang, Y., Ma, L., Wang, X., Liu, L., Zhang, Y., Jin, R., Ren, Z., Deng, Y., Shen, J., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01047-6 · Cited by 26 · see citing works

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

Esnault, C., Schrama, D., Houben, R., Guyétant, S., Desgranges, A., Martin, C., Berthon, P., Viaud‐Massuard, M., Touzé, A., Kervarrec, T., et al. (2022) · Cancers · doi:10.3390/cancers14030778 · Cited by 24 · see citing works

Abstract 4591: Specific elimination of invasive and multidrug-resistant cancer cells by an antibody-drug conjugate targeting AXL

Boshuizen, J., Koopman, L. A., Breij, E. C. W., Satijn, D. P. E., Peeper, D. S., & Parren, P. W. H. I. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-4591 · Cited by 1 · see citing works

AXL inhibition improves BRAF-targeted treatment in melanoma

Nyakas, M., Fleten, K. G., Haugen, M. H., Engedal, N., Sveen, C., Farstad, I. N., Flørenes, V. A., Prasmickaite, L., Mælandsmo, G. M., & Seip, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-09078-z · Cited by 50 · see citing works

25 Strategies to overcome phenotype switch-driven therapy resistance in melanoma

Boshuizen, J., Koopman, L. A., Vredevoogd, D. W., Ligtenberg, M. A., Breij, E. C. W., & Peeper, D. S. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-eacr25.25

Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma

Karlsen, K. F., McFadden, E., Omar, N., Haugen, M. H., Øy, G. F., Ryder, T., Gullestad, H. P., Hermann, R., Mælandsmo, G. M., & Flørenes, V. A. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0290 · Cited by 24 · see citing works

469 Analyzing resistance of AXL- and/or MITF-expressing melanoma cells to immunotherapy

Willemsen, M., Bakker, W. J., Bulgarelli, J., Chauhan, S., Angeli, D., Lereim, R. R., Davidson, I., Kyte, J.-A., Guidoboni, M., & Luiten, R. M. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.09.483